Literature DB >> 2090672

Cyclical Cushing's disease and its successful control under sodium valproate.

A Beckers1, A Stevenaert, G Pirens, P Flandroy, J Sulon, G Hennen.   

Abstract

Several subgroups of Cushing's disease were recently described (anterior or intermediate lobe origin, hyper-or hypo-pulsatility of cortisol, presence or absence of response after GRH or TRH, cyclical Cushing's disease). We present here a detailed case report on a patient suffering from Cushing's disease whose endocrine functions were extensively investigated. Treatment with bromocriptine, as well as subsequent transsphenoidal surgery, were followed by rapid but transient reversal of symptoms. When clinical manifestations reoccurred, daily measurements of free urinary cortisol revealed a cyclic pattern of cortisol hyperexcretion. A study of ultradian rhythm revealed hyperpulsatility of cortisol secretion. More interestingly, a treatment with sodium valproate, a drug known to inhibit CRH production, was followed by a rapid and longstanding normalization of clinical and biological data for 2 years. Based on these data, and on information from the literature, the present case of Cushing's disease exhibits characteristics suggesting a possible hypothalamic origin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2090672     DOI: 10.1007/BF03349657

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  27 in total

1.  Fluctuation in the excretion of adrenocortical steroids in a case of Cushing's syndrome.

Authors:  G BIRKE; E DICZFALUSY
Journal:  J Clin Endocrinol Metab       Date:  1956-02       Impact factor: 5.958

2.  Response to neurotransmitter modulating drugs in patients with Cushing's disease.

Authors:  H P Koppeschaar; R J Croughs; J H Thijssen; F Schwarz
Journal:  Clin Endocrinol (Oxf)       Date:  1986-12       Impact factor: 3.478

3.  Size reduction of an ACTH-secreting pituitary macroadenoma in Nelson's syndrome by sodium valproate: effect of withdrawal and re-institution of treatment.

Authors:  P Loli; M E Berselli; F Vignati; C De Grandi; M Tagliaferri
Journal:  Acta Endocrinol (Copenh)       Date:  1988-11

4.  Cushing's disease with periodic hormonogenesis: one explanation for paradoxical response to dexamethasone.

Authors:  R D Brown; G R Van Loon; D N Orth; G W Liddle
Journal:  J Clin Endocrinol Metab       Date:  1973-03       Impact factor: 5.958

5.  Successful treatment with sodium valproate of a patient with Cushing's disease and gross enlargement of the pituitary.

Authors:  H P Koppeschaar; R J Croughs; J W van't Verlaat; M J Hendriks; C J Arts; J H Thijssen; F Schwarz
Journal:  Acta Endocrinol (Copenh)       Date:  1984-12

6.  Adrenocorticotropin-secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing's disease: differences in the regulation of hormone secretion.

Authors:  S W Lamberts; S A de Lange; S Z Stefanko
Journal:  J Clin Endocrinol Metab       Date:  1982-02       Impact factor: 5.958

7.  Algorithms for the study of episodic hormone secretion.

Authors:  G R Merriam; K W Wachter
Journal:  Am J Physiol       Date:  1982-10

8.  Dynamics of adrenocorticotropin (ACTH) secretion in cyclic Cushing's syndrome: evidence for more than one abnormal ACTH biorhythm.

Authors:  R M Jordan; A Ramos-Gabatin; J W Kendall; D Gaudette; R C Walls
Journal:  J Clin Endocrinol Metab       Date:  1982-09       Impact factor: 5.958

9.  Early normalization of luteinizing hormone pulsatility after successful transsphenoidal surgery in women with microprolactinomas.

Authors:  A Stevenaert; A Beckers; J L Vandalem; G Hennen
Journal:  J Clin Endocrinol Metab       Date:  1986-05       Impact factor: 5.958

10.  Sodium valproate and cyproheptadine may independently induce a remission in the same patient with Cushing's disease.

Authors:  H P Koppeschaar; R J Croughs; J H Thijssen; F Schwarz
Journal:  Acta Endocrinol (Copenh)       Date:  1983-10
View more
  8 in total

Review 1.  Molecular basis of pharmacological therapy in Cushing's disease.

Authors:  Diego Ferone; Claudia Pivonello; Giovanni Vitale; Maria Chiara Zatelli; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

Review 2.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

3.  Failure of long-term therapy with sodium valproate in Cushing's disease.

Authors:  A Colao; R Pivonello; F S Tripodi; F Orio; D Ferone; G Cerbone; C Di Somma; B Merola; G Lombardi
Journal:  J Endocrinol Invest       Date:  1997 Jul-Aug       Impact factor: 4.256

4.  Cyclic Cushing's disease with paradoxical response to dexamethasone.

Authors:  S Checchi; L Brilli; E Guarino; C Ciuoli; G Di Cairano; P Mazzucato; F Pacini
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

Review 5.  Cyclic Cushing's syndrome: an overview.

Authors:  Franco Mantero; Carla M Scaroni; Nora M E Albiger
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

Review 6.  Pituitary disorders. Drug treatment options.

Authors:  J J Orrego; A L Barkan
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

7.  A pitfall of bilateral inferior petrosal sinus sampling in cyclic Cushing's syndrome.

Authors:  Adriana Albani; Christina M Berr; Felix Beuschlein; Marcus Treitl; Klaus Hallfeldt; Jürgen Honegger; Günter Schnauder; Martin Reincke
Journal:  BMC Endocr Disord       Date:  2019-10-22       Impact factor: 2.763

8.  Resolution of Cyclicity After Pasireotide LAR in a Patient With Cushing Disease.

Authors:  Márcio Carlos Machado; Valter Angelo Sperling Cescato; Maria Candida Barisson Villares Fragoso; Marcello Delano Bronstein
Journal:  AACE Clin Case Rep       Date:  2021-03-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.